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Abstract
Background: Heterozygosity of TP53 missense mutations is related to the phenomenon of the dominant-negative
effect (DNE). To estimate the importance of the DNE of TP53 mutations, we analysed the percentage of cancer
cases showing a single heterozygous mutation of TP53 and searched for a cell line with a single heterozygous
mutation of this gene. This approach was based on the knowledge that genes with evident DNE, such as EGFR
and IDH1, represent nearly 100% of single heterozygous mutations in tumour specimens and cell lines.
Methods: Genetic analyses (LOH and sequencing) performed for early and late passages of several cell lines
originally described as showing single heterozygous TP53 mutations (H-318, G-16, PF-382, MOLT-13, ST-486 and
LS-123). Statistical analysis of IARC TP53 and SANGER databases. Genetic analyses of N-RAS, FBXW7, PTEN and STR
markers to test cross-contamination and cell line identity. Cell cloning, fluorescence-activated cell sorting and SSCP
performed for the PF-382 cell line.
Results: A database study revealed TP53 single heterozygous mutations in 35% of in vivo (surgical and biopsy)
samples and only 10% of cultured cells (in vitro), although those numbers appeared to be overestimated. We deem
that published in vivo TP53 mutation analyses are not as rigorous as studies in vitro, and we did not find any cell
line showing a stable, single heterozygous mutation. G16, PF-382 and MOLT-13 cells harboured single
heterozygous mutations temporarily. ST-486, H-318 and LS-123 cell lines were misclassified. Specific mutations, such
as R175H, R273H, R273L or R273P, which are reported in the literature to exert a DNE, showed the lowest
percentage of single heterozygous mutations in vitro (about 5%).
Conclusion: We suggest that the currently reported percentage of TP53 single heterozygous mutations in tumour
samples and cancer cell lines is overestimated. Thus, the magnitude of the DNE of TP53 mutations is questionable.
This scepticism is supported by database investigations showing that retention of the wild-type allele occurs with
the same frequency as either nonsense or missense TP53 mutations.
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Background
Single heterozygous mutations of TP53 are associated
with gain-of-function (GOF) phenomena and, especially,
the dominant-negative effect (DNE) [1,2]. Nonetheless,
GOF can be attributed to hemizygous or homozygous,
as well as heterozygous, mutations [3]. DNE may be
linked to many processes, including the effectiveness of
chemotherapy and the failure of TP53 gene therapy
[4,5]. Dominant-negative TP53 mutations are frequently
described as very strong, completely abolishing the func-
tion of the wild-type protein [6]. Nevertheless, certain
observations undermine the importance of the dominant-
negative effect of missense heterozygous mutations.
According to Dearth et al., approximately 60% of tumours
with a missense mutation in TP53 have lost the wild-type
allele, making a case against the absolute importance of
the dominant-negative effect [7]. Moreover, Heyne et al.
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dominant inhibition [8]. Li-Fraumeni patients’ fibroblasts,
exhibiting single heterozygous mutations, did not demon-
strate clear alterations in vital functions [9]. The majority
of work focusing on the dominant-negative effect and
gain-of-function were performed under artificial model
conditions using plasmids to express wild-type and
mutated TP53. [10,11]. Other opportunities were offered
by a rodent animal model [12]; however, the mouse model
does not represent an exact human counterpart. To this
end, we proposed an alternative approach to evaluate the
significance of TP53 mutations DNE. Cell lines directly
derived from human cancers with heterozygous TP53
mutations may be more relevant, and thus, we searched
for cell lines with a single heterozygous TP53 mutation.
Because haplo-insufficiency is not attributed to TP53, the
percentage of cases demonstrating single heterozygous
mutations can be used to estimate the importance of TP53
mutations DNE. Obviously, genes such as IDH1 and
EGFR, for which a DNE is clearly observed, exhibit almost
exclusively single heterozygous mutations [13,14]. More-
over, studies report differences and gradations for specific
mutations [7,15]. This prompted us to perform a more
complex analysis of databases and cell lines to estimate
the percentage of single heterozygous TP53 mutations
and, thus, the importance of TP53 mutations DNE. Our
approach is in accordance with the suggestion of Olivier’s
group to consider the percentage of cases showing loss of
heterozygosity (LOH) in the estimation of DNE impor-
tance [15]. As they have hypothesized, thorough assess-
ment of the role of DNE in cancer development requires
knowledge of the status of 17p LOH in tumours [15].
Furthermore, apart from LOH status, we have also ana-
lysed the occurrence of double mutations of TP53. More-
over, we have broadened the spectrum of results obtained
from databases by analysing several cell lines in vitro.
Methods
Cultured Samples
The study included human cancer cell lines, cultured
cells and corresponding tumour samples. Commercially
available human cancer cell lines PF-382 and MOLT-13
were obtained from German Collection of Microorgan-
isms and Cell Cultures (DSMZ), Braunschweig,
Germany. Cell lines ST-486 and LS-123 were obtained
from American Type Culture Collection (ATCC) Mana-
ssas, USA. H-318 mouse cell line was kindly provided
by Professor Guillermina Lozano, Department of Cancer
Genetics, The University of Texas M. D. Anderson Can-
cer Center, Houston. Cells were cultured in RPMI 1640
or MEM supplemented with 10% FBS (PAA, Linz,
Austria) and penicillin/streptomycin/glutamin (GIBCO
BRL, Paisley, UK), in 5% CO2. G-16 cultured cells were
established from a surgically resected tumour from a
patient diagnosed with glioblastoma. Archival paraffin
sections of the tumour, from which G-16 cells were
derived, were obtained from the Department of Pathol-
ogy, Medical University of Lodz. G-16 cells were cul-
tured in MEM supplemented with 10% FBS (PAA, Linz,
Austria) and penicillin/streptomycin/glutamin (GIBCO
BRL, Paisley, UK), in 5% CO2.
Database Analysis
Our analysis of TP53 mutation status in human cancer
cell lines and tumour samples was performed using two
databases: the Sanger Institute Catalog Of Somatic
Mutations In Cancer (COSMIC) that gathers informa-
tion on genetic alterations (taken from the literature
and in-house sequencing in human tumour samples and
tumour cell lines), and the IARC TP53 Mutation Data-
base that compiles all TP53 gene variations identified in
human populations and tumour samples [15-18]. Analy-
sis was confirmed using the TP53 Mutation Handbook -
the last release of the UMD_p53 database, that collects
information on the TP53 status in cell lines published
between 1989 and 2008 [19]. The data were organized
into 2 × 2 tables according to given variables and Χ
2
(chi squared) test was performed.
DNA and RNA Extraction
Total cellular DNA and RNA were isolated from cell
lines, cultured samples, frozen tissues (stored at -80°C)
and frozen leukocytes of peripheral blood obtained from
healthy volunteers and the patients using AllPrep DNA/
RNA Mini Kit (Qiagen, Germany) according to the
manufacturer’s protocol. RNA samples were treated
with DNase. RNA and DNA concentrations were mea-
sured spectrophotometrically. 100 ng of total RNA was
reversetranscribed into single-stranded cDNA in a final
volume of 40 μl containing 50 mM DTT, 1.5 μgo l i g o
(dT), 0.5 mM dNTP, 40 units RNase inhibitor and
200 units M-MLV reverse transcriptase (Promega).
DNA Extraction from Archival Formalin-fixed Paraffin-
embedded Blocks
Specimens from a patient diagnosed with glioblastoma
(classified according to the World Health Organization
criteria for the classification of brain tumours) were
obtained from the Department of Pathology, Medical
University of Lodz. Tissue samples were fixed with 4%
neutralized formalin and embedded in paraffin. Before
tissue processing, histopathological examination of those
specimens with H&E staining was necessary to confirm
the target areas of tissue for DNA extraction. The same
areas in the paraffin blocks were matched to accurately
locate the target tissue for scraping. Two different
marked target areas from paraffin block were carefully
scraped with the surgical blade, to a maximum depth of
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tissue. The scraped tissues were collected into 2 ml
Eppendorf tubes, de-paraffinized with xylene, washed
with ethanol and dried. 200 μl lysis buffer containing
approximately 1 μg/μl KCev PRoteinase (Roche Diag-
nostics, Mannheim, Germany) was added to each tube
and digested at 55°C overnight. DNA was then purified
and extracted with phenol, phenol/chloroform mixture
and chloroform, precipitated with 98% ethanol and
dried in a speed vacuum. The obtained DNA was dis-
solved in 20 μl TE buffer.
Loss of Heterozygosity Analysis (STR Analysis)
Loss of heterozygosity analysis (LOH) was performed
using paired tumour specimens and corresponding per-
ipheral blood samples. The following LOH markers
were used: D17S1828, D17S976. Twenty additional mar-
kers were used for cross contamination analysis. The
forward primers were 5’-end-fluorescence-labeled. PCR
was performed in thermocycling conditions individually
established for each pair of primers. Approximately 0.5
μl of each PCR product was denatured and gel electro-
phoresis in LiCor automatic sequencer system (Lincoln,
NE) was applied for the separation and analysis of PCR-
generated alleles. LOH was assigned when the intensity
of the tumour alleles differed by at least 50% from that
observed in the corresponding control DNA. STR analy-
sis allowed to exclude possible cross contamination of
analysed cell lines excluding H-318 (murine cell line).
Single Strand Conformation Polymorphism (SSCP)
Exon 8 of the TP53 gene was amplified by PCR on DNA
template in standard conditions 32x (92°C, 55°C, 72°C)
using the 5’-end-fluorescence-labeled primers and muta-
tions were detected by SSCP analysis. For SSCP analysis,
PCR product was mixed with gel loading buffer (95%
formamide, 20mM EDTA, 0.05% bromophenol blue and
0.05% xylene cyanole). The mixture was heat-denatured
at 100°C for 5 min and rapidly chilled on ice. Denatured
products were loaded on to the polyacrylamide gel sup-
plemented with 10% glycerol and gel electrophoresis in
LiCor automatic sequencer system (Lincoln, NE) was
applied for the analysis.
TP53 DNA and cDNA Sequencing
Exons from 2 to 11, introns from 4 to 8 and 3’UTR
region of the TP53 gene were amplified by PCR on
DNA template in standard conditions 32x (92°C, 55°C,
72°C) and sequenced using the dideoxy termination
method and SequiTherm Excel DNA Sequencing Kit
(Epicentre Technologies) following the protocol of man-
ufacturer. Exons 5-8 of the TP53 gene were amplified by
PCR on cDNA template as described before and
sequenced using the dideoxy termination method and
SequiTherm Excel DNA Sequencing Kit (Epicentre
Technologies) [20]. To verify the results of sequencing
the semiquantitative densitometric analysis was per-
formed. The intensity of wild-type and mutated bands
was estimated by comparing them to the neighbouring
bands in the same sequencing lane used as a reference.
Primer sequences provided as supporting information.
Single Cell-cloning
In order to yield a homogeneous cell population, several
cell lines were established by single-cell cloning from the
primary culture of PF-382 cells provided by German Col-
lection of Microorganisms and Cell Cultures, Braunsch-
weig, Germany. Cloning was performed by limiting
dilution into 96-well plates. Clonality was assessed imme-
diately by microscopic observation to identify wells con-
taining only a single cell. Among the clones, two rapidly
growing lines, cell line A and B, were selected for further
analysis based on DNA and cDNA sequencing, and com-
pared with primary PF-382 cells and each other.
Cell Sorting
PF-382 cell line was sorted under non-sterile conditions
to retrieve subpopulations for DNA extraction and for
morphological analysis. Cells from culture were centri-
fuged for 5 min at 1 500 rpm, washed three times in PBS
at 37°C for 5 minutes. After this, cells were fixed with 4%
paraformaldehyde at 4°C for 15 minutes and again centri-
fuged for 5 min at 1 500 rpm and then washed three
times in PBS at 4°C for 5 minutes. For sorting, fixed cells
were resuspended in 3 ml PBS. Light scatter parameters
were used to establish sorting gates to distinguish the
subpopulations of viable, apoptotic and dead cells. The
analysis and separation of 1 000 000 cells was performed
using FACSAria II cell sorter (BD Biosciences).
Results
Database Analysis
Analysis of the Sanger and IARC databases with respect
to TP53 status in surgical and biopsy samples and in
cultured cells yielded the results presented in Figure 1.
Most importantly, the percentage of surgical and biopsy
specimens described as single heterozygous was very
high (35%) compared to cultured cancer cell lines sup-
posedly carrying such a mutation (10%) (Figure 1A, 1B).
Cell lines show a lower proportion of wild-type TP53
retention because of more frequent 17p LOH and sec-
ond heterozygous TP53 mutations (Figure 1C). The per-
centage of samples with at least one mutation outside
exons 5-8 is higher in cancer cell lines, with at least two
mutations, than in tumour samples with two mutations
(42% in cell lines and 31% in tumour samples - not sta-
tistically significant) (Figure 1D). The frequency of
retention of the wild-type allele in cancer cell lines with a
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amongst cancer cell lines with a nonsense mutation
(Figure 1E). Additionally, our database analysis per-
formed two years ago demonstrated that several cell lines
harbour a single heterozygous mutation. Currently, the
following cell lines are described as showing two, three
or more mutations: CMK, Cha-Go-K-1 and NCI-H661,
respectively. The status of the MOLT-16, KM-12,
SK-LMS-1, J-82, Daudi and Raji cell lines remains con-
troversial; the Sanger database lists these cell lines as pos-
sessing a single mutation, whereas the TP53 Mutation
Handbook shows them as having two or more mutations.
Additionally, database analysis provided important infor-
mation regarding TP53 hot-spot mutations (Figure 1F).
Codon 248 exhibited the highest percentage of in vivo sin-
gle heterozygous mutations, whereas the percentage of in
Figure 1 The statistical analyses of databases. (A) A comparison of TP53 wild type allele retention occurrence in human cancer cell lines with
samples from surgeries and biopsies (marked as tumour samples) showing mutation, Χ
2 test was performed for cell lines vs tumour samples. (B)
A comparison of ROH/LOH 17p occurrence in human cancer cell line showing mutation and tumour samples, Χ
2 test was performed. (C) A
comparison of incidence of 1/more than 1 TP53 mutation in human cancer cell lines and tumour samples, Χ
2 test was performed. (D) A
comparison of TP53 wild type allele retention occurrence in human cancer cell lines and tumour samples with the distinction between missense
and nonsense mutation (sample was categorized as “missense” in case of at least 1 missense mutation, while “nonsense” with no missense
mutations), Χ
2 test was performed for cell-lines and tumour samples separately. (E) A comparison of incidence of at least one TP53 mutation
outside exons 5-8 versus all TP53 mutations within exons 5-8 in human cancer cell lines and tumour samples showing 2 or more TP53
mutations, Χ
2 test was performed. (F) A comparison of TP53 wild type allele retention occurrence in human cancer cell lines and tumour
samples with mutations characteristic for dominant-negative effect (codons 175, 248, 273, with distinction for R273C, as with no DNE, and other
types of mutation of codon 273 - marked R273X), Χ
2 test was performed for each analysis.
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of TP53. Codon 175 demonstrated a very low percentage
of single heterozygous mutations in vitro and an average
percentage in vivo. Analysis of codon 273 provided addi-
tional information, specifically, that mutation R273C was a
single heterozygous mutation in approximately 20% of cell
lines, both in vivo and in vitro. For other mutations of this
codon, the incidence was 42% and 5% in vivo and in vitro,
respectively.
G-16 Analysis
A surgical specimen of glioblastoma (GBM) was ana-
lysed by sequencing and LOH analysis. A mutation in
codon 272 was observed with both wild-type and
mutated templates, although the band representing the
latter was faint. In addition, retention of heterozygosity
of 17p was shown by means of D17S1828 and D17S976.
Cells grown under standard conditions showed the 272
mutation, but no 17p LOH at the 0 passage. However,
after 4 passages, the mutated template became more
apparent, and 17p LOH became detectable. After 10
passages, only the mutated template was present and
LOH analysis demonstrated only one allele (Figure 2).
DNA was isolated from a paraffin block as well. The
isolation from one target area showed LOH of 17p and
ROH in another region, with both fragments exhibiting
TP53 mutations. Sequencing analysis also revealed dif-
ferences in TP53 status. One tumour compartment (one
paraffin block fragment) suggested a heterozygous muta-
tion, whereas another exhibited a hemizygous mutation.
This analysis demonstrated that the glioblastoma speci-
men consisted of components presenting 17p ROH and
LOH, specifically, the retention and the loss of the wild-
type TP53 allele. We conclude that cell culture under
standard conditions selected for cells harbouring the
TP53 hemizygous mutation.
H-318 Analysis
The H-318 (adenocarcinoma) cell line was provided by
Professor Guillermina Lozano, Department of Cancer
Genetics, The University of Texas M. D. Anderson Can-
cer Center, Houston. This cell line was derived from a
cancer specimen described as having a heterozygous
mutation at codon 173 (equivalent of human TP53
codon 175) [21]. However, our DNA analysis showed
the presence of only the mutated template. Consultation
with the Lozano lab confirmed that the cell line was
derived from a tumour showing the mutation of one
allele and the retention of the second, wild-type allele
(Figure 3A).
MOLT-13 Analysis
The MOLT-13 cell line (T-cell leukaemia) was provided
by DSMZ. Originally, the cells contained a heterozygous
mutation, R273H, in TP53 (Figure 4A). An equivalent
ratio of wild-type to mutated template was detected
using DNA and cDNA analysis. After 2 months of cell
culture, the wild-type cDNA was absent in the analysed
sample. However, the genomic DNA still exhibited
equal amounts of mutated and wild-type template at
codon 273 (Figure 4B). This observation prompted us to
once again perform full-gene DNA sequencing, which
r e v e a l e dan o n s e n s em u t a t i o ni ne x o n4( t h e s ec e l l s
were labelled MOLT-13 boost). Only one interpretation
o ft h e s er e s u l t sw a sr e a s o n a b l e :am i s s e n s em u t a t i o no f
o n ea l l e l ea n dan o n s e n s em u t a t i o no ft h es e c o n da l l e l e
caused nonsense-mediated mRNA decay, which was
confirmed by polymorphism analysis of allele 72. Both
DNA and cDNA showed traces of the original heterozy-
gous codon 72, whereas analysis of further passages
Figure 2 Molecular analysis of G-16 glioblastoma cultured cells
and paraffin block fragments. (A) Examples of LOH analysis
showing deletion in 17p region at passage 10 (D17S1828 and
D17S976 markers were used) and occurrence of the subpopulation
of cells with 17p LOH in vivo (D17S1828 marker was used). Only a
trace of the lost allele is observed in the 10 passage of G-16
cultured cells and in the paraffin block fragment A. The lost allele is
marked with an arrow. (B) TP53 DNA sequencing results. The
mutated nucleotide (TP53 exon 8, codon 272, GTG > ATG, Val >
Met) is marked with arrows. 1) G-16 cultured cells at passage 4, G
and A nucleotides are both detected, representing a heterozygous
mutation. 2) G-16 cultured cells at passage 10, no wild type, only
mutated nucleotide is detected. 3) Normal control template, only
wild type DNA is detected. 4) G-16 paraffin block fragment A, both
nucleotides are detected but G nucleotide is faint, suggesting a
hemizygous mutation. 5) G-16 paraffin block fragment B, G and A
nucleotides are both detected, representing a heterozygous
mutation. N - corresponding normal tissue (blood) or normal,
control template; A - G-16 paraffin block fragment A; B - G-16
paraffin block fragment B; 0, 4, 8, 10 - numbers of passages.
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the DNA level and expression of only one allele at the
cDNA level (Figure 4). We considered that the second
mutation could have been generated in our laboratory,
or that an extremely small subpopulation of cells with
the two mutations was selected. To this end, MOLT-13
cells were thawed at the earliest possible passage and
again cultured for several months. After 4 weeks, we
again observed the same second mutation. The popula-
tion with two mutations required eight weeks to become
dominant. This observation provided convincing evi-
dence that the population with both missense and non-
sense mutations was selected from cells provided by
D S M Z .T h ei d e n t i t yo ft h i sc e l ll i n ew a sc o n f i r m e db y
FBXW7, PTEN, N-RAS and STR analysis (Figure 4C).
PF-382 Analysis
The PF-382 cell line, derived from a T-cell leukaemia,
was described as harbouring a single heterozygous
mutation, R273C. DNA analysis showed two mutations
at codon 273 of the TP53 gene (C817T and G818A).
The sequencing product showed that the second muta-
tion (818G > A) represented less than 30% of the
observed template after the first passage (Figure 5A). To
this end, cloning of PF-382, as well as fluorescence-acti-
vated cell sorting (FACS), was performed. Both techni-
ques revealed that the second mutation, together with
the original change, was observed only in a subpopula-
tion of cells. SSCP analysis showed that both mutations
(R273C and R273H) were localized on different alleles.
Figure 5 PF-382 cell line DNA sequencing analysis. (A) TP53
gene sequencing at passage 1. Two mutations in codon 273 are
visible (nucleotide 817C > T as originally described, and surprisingly,
818 G > A). The first mutation represents heterozygous status, equal
amounts of mutated and wild type allele are detected. The
sequencing product shows that the wild-type nucleotide is visible
as a strong band and mutated nucleotide is visible as a very weak
band in the second mutation. (B) Cloning of PF-382 primary culture
and TP53 sequencing after the following months of cell culturing
shows that intensity of mutated band has changed. (C) N-RAS DNA
sequencing. In order to confirm PF-382 cell line identity, mutation
of N-RAS gene was verified. N-RAS sequencing shows a
heterozygous mutation in codon 12 (N-RAS, GGT > AGT, Gly > Ser).
Mutations are marked with arrows. N - normal, control template;
A - colony.
Figure 4 MOLT-13 and MOLT-13 boost DNA and cDNA
sequencing analysis. (A) MOLT-13 TP53-sequencing. 1. DNA
analysis shows a heterozygous mutation in codon 273 (TP53, exon
8, CGT > CAT, Arg > His) and a heterozygous polymorphism in
codon 72 (TP53, exon 4, CGC > CCC, Arg > Pro), identical ratio of
wild type to mutated template was detected. 2. cDNA sequencing
confirms DNA results. (B) MOLT-13 boost TP53-sequencing. 1. DNA
analysis shows a heterozygous mutation in codon 273 and,
surprisingly, a deletion of one nucleotide - a nonsense mutation - in
exon 4 (both wild type and mutated template are visible). 2. cDNA
analysis showed only mutated nucleotide in codon 273
(representing hemizygous mutation) and only one allele expression
in exon 4. These results suggest a missense mutation of one allele
and a nonsense mutation of the other causing the nonsense mRNA
decay. (C) FBXW7 and N-RAS DNA sequencing. In order to confirm
MOLT-13 cell line identity, mutations of FBXW7 and N-RAS gene
were verified. 1. FBXW7 analysis shows a heterozygous mutation in
codon 465 (FBXW7, CGT > CAT, Arg > His). 2. N-RAS sequencing
shows a heterozygous mutation in codon 12 (N-RAS, GGT > GAT,
Gly > Asp). Mutations are marked with arrows. N - normal, control
template.
Figure 3 H-318, ST-486 and LS-123 cell lines TP53 sequencing
analysis. (A) H-318 mouse adenocarcinoma cell line TP53
sequencing. The mutated nucleotide (TP53 exon 5, codon 172, CGC
> CAC, Arg > His) is marked with an arrow. Only the mutated DNA
is detected, suggesting a hemi/homozygous mutation. (B) ST-486
cell line sequencing. 1. DNA analysis showed a heterozygous
mutation in codon 158 (TP53 exon 5, CGC > CAC, Arg > His), both
mutated and wild-type nucleotides are detected. 2. Exon 7
sequencing showed the second - heterozygous mutation (TP53,
codon 239, AAC > GAC, Asn > Asp), both nucleotides are visible. (C)
LS-123 cell line DNA sequencing, the mutated nucleotide (TP53
exon 5, codon 175, CGC > CAC, Arg > His) is marked with an arrow.
The analysis shows undetectable wild type DNA, suggesting homo/
hemizygous mutation. Mutated nucleotides are marked with arrows.
N - normal, control template.
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slow expansion of the population with both mutations
(Figure 5B). The provider of the PF-382 cells did not
offer information that would allow us to define the loca-
tion of the second mutation. The identity of this cell
line was confirmed by FBXW7, PTEN, N-RAS and STR
analysis (Figure 5C).
LS-123 and ST-486 Analysis
ST-486 cells were derived from a specimen of Burkitt’s
lymphoma, and LS-123 (large intestine adenocarcinoma)
cells were originally described as carrying a heterozy-
gous mutation in TP53 [18]. However, later analysis
indicated the presence of two mutations in ST-486 cells.
Our analysis confirmed this discovery (Figure 3B).
Apparently, both mutations were present from the
beginning of the ST-486 culture; however, the mutation
in exon 7 was omitted, despite being present during the
initial analysis.
Line LS-123 is still described as exhibiting a heterozy-
gous mutation of TP53 in the Sanger database. None-
theless, our analysis clearly shows that the wild-type
allele is lacking in these cells (Figure 3C).
Discussion
To properly judge the importance of heterozygous
mutations in TP53, an appropriate model for its analysis
is required. Heterozygosity of TP53 mutations is the
basis of the dominant-negative effect. For the most part,
the analyses of this phenomenon have been performed
in artificial systems and using animal models. However,
co-transfection of wild-type and mutated cDNA is artifi-
cial and does not allow for the analysis of all aspects of
gene function, and animal models do not represent
exact human counterparts [7]. To this end, the analysis
of human cancer cell lines with single heterozygous
TP53 mutations could be an alternative. However, this
approach features some caveats as well. Despite the fact
that a percentage of surgical and biopsy specimens that
are described as harbouring a single heterozygous muta-
tion is very high (35%), the proportion of cultured can-
cer cell lines supposedly carrying such a mutation is
lower (10%) (Figure 1A, 1B). Moreover, based on our
analysis, even this number appears to be overestimated.
These differences should be investigated in order to esti-
mate the importance of the dominant-negative effect of
TP53 mutations. A higher percentage of single heterozy-
gous mutations indicates a greater importance of domi-
nant-negative effect, as has been shown for genes such
as IDH1 or EGFR [13,14].
First, genetic heterogeneity can sometimes be mista-
ken for the heterozygous status of the TP53 gene. In
cancer specimens exhibiting a TP53 mutation, cells
without a mutation are present as well. TP53 is mutated
at the end of the mutation pathway, and many cancer
cells without a mutation in this gene can be observed
within the specimen [22-25].
Another explanation for the discussed discrepancies
may be the more thorough genetic analysis of TP53
gene sequences in cell lines compared to tumour sam-
ples, which implies that cell line studies are more reli-
able in this respect. For the most part, tumour samples
(especially where paraffin blocks are concerned) do not
provide a sufficient amount of high-quality DNA to
repeatedly analyse all TP53 gene elements. The percen-
tage of single heterozygous mutations is lower than sug-
gested by in vivo analysis, and thus, the importance of
the DNE of TP53 mutations is undermined. Database
analysis supports such a possibility. Interestingly, cell
lines exhibit a lower proportion of wild-type TP53
r e t e n t i o n ,n o tm e r e l yb e c a u s eo ft h em o r ef r e q u e n t1 7 p
LOH, but also due to the more frequent second hetero-
zygous TP53 mutation (Figure 1C). The percentage of
samples with at least one mutation outside exons 5-8 is
higher in cancer cell lines with at least two mutations
than in cancer surgical samples with two mutations
(42% in cell lines and 31% in tumour samples) (Figure
1D). Although the difference is not statistically signifi-
cant, the investigation of this discrepancy leads to the
suspicion that some of the mutations outside region 5-8
were not detected due to negligence during the analysis
of surgical and biopsy samples. It has been confirmed in
many cell line analyses that the first examination is not
sufficiently thorough, whereas surgery/biopsy sample
analyses are rarely repeated [26-28]. The TE-3 cell line
is a good example of this issue. In the first paper, the
lack of a mutation was suggested [26]; however, an addi-
tional analysis revealed a homozygous splice-site muta-
tion in intron 4 of TP53 [27]. Importantly, TE-3 cells
were initially shown as lacking the TP53 protein [26].
Apparently, an undetected homozygous nonsense muta-
tion was the reason for the absence of TP53 protein.
This problem can also be demonstrated using the ST-
486 cell line. Originally described as exhibiting one het-
erozygous mutation, ST-486 has currently been rede-
fined as harbouring two mutations [28]. Our analysis
confirmed the presence of the two mutations in ST-486
cells (Figure 3B). The data presented here suggest the
overestimation of the proportion of heterozygous TP53
mutations, both in vivo and in vitro.N o t w i t h s t a n d i n g ,
this information cannot fully account for the discussed
(in vivo - in vitro) TP53 discrepancies, which are crucial
for estimating the dominant-negative effect of TP53
mutations. Intriguingly, the list of cell lines showing a
single heterozygous mutation of TP53 is diminishing.
The process of cell line reclassification is currently very
vigorous. The Sanger Database features many cell lines
that have changed status within the last 2 years, from
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more than one mutation (vide cell lines: CMK, Cha-
Go-K-1 and NCI-H661). It is highly unlikely that each
pair of double mutations affected the same allele. More-
over, some cell lines are reported differently between
databases: MOLT-16, KM-12, SK-LMS-1, J-82, Daudi
and Raji. Notably, the LS-123 cell line, which is still cat-
alogued as heterozygous, was provided to us with a
hemizygous TP53 mutation (Figure 3C). The reasons for
these on-going changes in the databases are not clear
because we are unable to determine whether the late
discovery of the second mutation is the result of its gen-
eration in vitro, selection of an originally small subpopu-
lation of cells with this mutation in vivo, experimental
errors or technical inaccuracies. The difficulty in discri-
minating between the first two potential explanations
will be the subject of the following paragraphs.
The in vitro selection of cells exhibiting a hemizygous
mutation “hidden” within cells with a heterozygous
mutation and the generation of 17p LOH or of a new
point mutation in the other allele (initially/in vivo wild-
type allele) may be vital in elucidating the lack of a sin-
gle TP53 heterozygous mutation in cell lines (Figure 6).
Our experimental analyses addressed both issues.
Data published by Lozano et al. and their analysis of
the H-318 cell line, which showed ROH of 17p, support
the latter scenario [21]. Nevertheless, our investigation
demonstrated the lack of the wild-type DNA template
(Figure 3A). These results suggest the elimination of the
wild-type allele during culturing. The conclusions of
Lozano et al. are modestly supported by the analysis
performed by Boyle et al. The loss of the wild-type allele
inv i t r owas well defined during the examination of
fibroblasts derived from patients with Li-Fraumeni syn-
drome [29]. These cells originally showed only a hetero-
zygous mutation, whereas after 15-20 passages, colonies
with 17p LOH were detected. Subsequently, the cells
with 17p LOH became dominant [29]. The analysis of
Li-Fraumeni patients’ fibroblasts supports Lozano’sc o n -
clusion; however, it is not certain whether the H-318
cell line derives from the selection for cells with a hemi-
zygous mutation or the generation of 17p LOH in vitro.
The phenomenon of the selection for cells with a
hemizygous mutation was exemplified by the deriva-
t i o no ft h eG - 1 6c e l ll i n eb yo u rl a b o r a t o r y .T h i sa n a l y -
sis showed the presence of at least two neoplastic
compartments, one with the heterozygous and the
other with the hemizygous mutation of TP53.T h i s
strongly suggests that selection for cells with the hemi-
zygous mutation, as opposed to its de novo generation,
was responsible for the discrepancies between the sur-
gical sample and the established cell line. The afore-
mentioned selection of cells without the wild-type
TP53 allele indicates that the dominant-negative effect
of TP53 mutations is less important than is generally
suggested. Clearly, a heterozygous mutation is not as
influential as a hemizygous, homozygous or double
heterozygous mutation. In some cases, we were not
able to precisely define whether the mutation was gen-
erated in vitro or selection had occurred. Nevertheless,
the cell lines described in the databases as carrying a
single heterozygous mutation appeared very unstable
in this state or were potentially misclassified. This may
be exemplified by the analysis of PF-382 cells. Our
study of this cell line revealed two mutations in codon
273 (Figure 5), although the databases indicate only a
single mutation. One of these mutations was originally
observed only in a subpopulation of cells. We could
not exclude that a subpopulation of cells exhibiting
two mutations was already present in vivo and was
later ignored during the original DSMZ investigation.
Alternatively, the second mutation may have been gen-
erated during the production of cell culture stocks.
SSCP analysis and cell cloning for PF-382 cells support
the conclusion that both mutations in codon 273
affected different alleles.
Figure 6 Two proposed hypotheses (generation and selection). (A) In vitro generation of 17p LOH or in vitro occurring selection of small
subpopulation of cells without wild type TP53 allele. (B) In vitro mutation of allele showing in vivo normal sequence or in vitro occurring
selection of small subpopulation of cells with 2 mutated TP53 alleles.
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results. The MOLT-13 cell line was provided to our
laboratory by DSMZ, and only one heterozygous muta-
tion in codon 273 of the TP53 gene was detectable in
the early passages. After 2 months of culturing under
standard conditions, the second mutation was detected
during a routine screening (Figure 4B), which prompted
us to restart the culture of the original MOLT-13 cells.
Culturing these cells for only four weeks produced cells
with both mutations, which established that the pre-
sence of cells with the two mutations was the result of
selection in our laboratory, rather than de novo genera-
tion. The data provided by DSMZ did not allow us to
exclude that the second mutation was not present in the
original patient sample and was generated during the
production of vendor stocks. In any case, if generation
or selection occurs in vitro, the importance of the domi-
nant-negative effect is undermined by the instability of
single heterozygous mutations, as well as the enhanced
in vitro survival of cells exhibiting a lack of wild-type
TP53.
The data presented above show that although surgical
specimens are analysed less precisely than cell lines, sin-
gle heterozygous mutations are still observed more fre-
quently in vivo than in vitro. The G16, MOLT13-boost
and PF-382 cell lines consist of cells that were selected
from subpopulations arising in vivo (in the case of the
MOLT13-boost minor subpopulation), whereas H-318
cells probably acquired the 17p LOH in vitro (adapta-
tion to in vitro conditions and further stages of tumori-
genesis). Thus, it may be presumed that it is possible to
detect many biological differences between cells
observed in vivo and in vitro in terms of TP53 status.
For example, artificial selection forces acting in vitro
m a yc h a n g et h eTP53 status. Alternatively, rapid selec-
tion and generation of subpopulations of the more
advanced neoplastic cells may be observed under such
conditions. The latter interpretation would favour in
vitro conditions as selecting the most effective impair-
ment of TP53, i.e., the selection of cells at more
advanced stages of carcinogenesis.
Nonetheless, an effective DNE would not be easily
replaced by elimination or impairment of the second
allele under artificial or in vivo selection pressure. More-
o v e r ,i ti sv e r yu n l i k e l yt h a tam e c h a n i s mt h a ti ss u f f i -
ciently effective in vivo would become utterly
suppressed in vitro. In general, in vitro selection and
generation of cells presenting hemi/homozygous muta-
tions undermines the importance of dominant-negative
inactivation of TP53.S t i l l ,w ec a n n o te x c l u d et h a tin
vitro cell culture does not optimally recapitulate all
aspects of tumorigenesis involving TP53.
We are aware that DNE has been presented many
times for some of the TP53 mutations. Our analysis
suggests that DNE TP53 mutations, which are albeit
limited in general, differ with respect to specific muta-
tions. First, the mutation R175H seems to exhibit a
weaker DNE than mutations in codon 248. Furthermore,
our results are very intriguing for DNE mutations in
codon 273 (R273L, R273P, R273H) in comparison to
R273C, a mutation exhibiting a lack of DNE, as demon-
strated by Dearth et al. In part, it could be expected
t h a tt h ep e r c e n t a g eo fs i n g l eh e t e r o z y g o u sm u t a t i o n s
correlates with the magnitude of DNE and the impor-
tance of specific dominant-negative mutations defined
by Dearth et al. Namely, the percentage of mutations in
codon 273 defined by Dearth et al. as exhibiting a DNE
was higher in vivo than this number for the R273C
mutation (42% vs. 23%). On the other hand, the percen-
tage of single heterozygous R273C mutations was 4
times higher in vitro than other mutations in this codon
(20% vs. 5%), undermining the importance of TP53
mutations DNE in vitro. Nevertheless, segregating TP53
mutations into hot spots changes the overall results very
little. None of the hot spots exhibit a percentage of sin-
gle heterozygous mutations higher than 50% (Figure 1F),
bearing in mind that these values are overestimated
according to our analyses. Still, the data do not imply a
complete lack of DNE. It may be inferred that DNE is a
mechanism operating solely in vivo,w h i c h ,h o w e v e r ,
remains in contradiction with the DNE model. More-
over, other tumour suppressor genes, such as APC and
Rb, also show similar differences between the frequency
of single heterozygous mutations in vivo and in vitro
[17,18]. Obviously, APC and Rb exhibit nonsense muta-
tions, and DNE is not attributed to these genes, whereas
epigenetic silencing is [30-33]. However, considering the
latter observation, another analysis of the database is
very appealing. The retention of the wild-type allele in
cancer cell lines with a missense TP53 mutation is
almost the same as the frequency amongst cancer cell
lines with a nonsense mutation (Figure 1E). This indi-
cates that a missense mutation does not predispose cells
to retain the wild-type TP53 allele any more than does a
nonsense mutation, whereas a dominant-negative effect
is expected to be the attribute of missense mutations
only. In our opinion, this suggests that the dominant-
negative effect can be confused with gain of function
and even mistaken for an unknown mechanism of wild-
type TP53 inhibition if a single heterozygous mutation
occurs. Our group has already demonstrated the predo-
minance of mutated mRNA over wild-type mRNA in
glioblastoma specimens showing putative single hetero-
zygous mutation of TP53 [20].
Conclusion
Considering all the data presented here, the DNE of
TP53 mutations seems to be less important than the
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gest. Nevertheless, this effect should not be ignored, and
we do not exclude that it plays an important role at the
earliest stages of tumorigenesis.
In conclusion, we summarize the following facts dis-
cussed in our article undermining the influence of the
dominant-negative effect of TP53 missense mutations:
- the percentage of TP53 single heterozygous muta-
tions described in databases is low (35% in vivo and
10% in vitro),
- the percentage of single heterozygous mutations in
cancer specimens (in vivo) is overestimated in
databases,
- the percentage of single heterozygous mutations in
cancer cell lines (in vitro) is overestimated in
databases,
- cancer cells exhibiting a lack of wild-type TP53 are
generated and/or selected for in vitro,
- the percentage of single heterozygous mutations of
TP53 is higher in cancer specimens than in cancer
cell lines,
- mutations considered to show DNE, R175H and
R273X (excluding R273C), represent about 5% of
single heterozygous mutations in vitro, according to
the IARC database,
- the frequency of retention of the wild-type allele in
cancer cell lines and tumour samples with a mis-
sense mutation is almost the same as the frequency
amongst cancer cell lines and tumour samples with
a nonsense mutation, according to databases.
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